Myeloma clinical outcomes following the first wave of COVID‐19: results from the Thames Valley Cancer Alliance (UK).

In the 15 patients who died, nine remained on therapy, ( I n i = 9/18, 50%), five ( I n i = 5/18, 27-8%) had their treatment paused for up to eight weeks, one patient had his treatment stopped altogether ( I n i = 1/18, 5-6%) and the exact modification was missing in the remaining three cases ( I n i = 3/18 = 16-7%). Baseline characteristics of patients who continued myeloma treatment (as per pre-COVID-19 plan) and those who had their myeloma disease management modified as a result of the COVID-19 pandemic (including stopping therapy), and their haematological response at the time and treatment regimen. Keywords: infection; myeloma; myeloma treatment EN infection myeloma myeloma treatment e136 e139 4 03/19/21 20210315 NES 210315 Concern for higher mortality in myeloma patients was reflected in the response to the first wave of the novel coronavirus SARS-CoV-2 (COVID-19) pandemic. In conclusion, this descriptive study of 219 MM patients illustrates how a systematic approach to a patient's risk of infection and individualised treatment modifications are possible and may have contributed to a low incidence rate of COVID-19 infection. [Extracted from the article]